GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (NEOE:LLY) » Definitions » Cyclically Adjusted PB Ratio

Eli Lilly and Co (NEOE:LLY) Cyclically Adjusted PB Ratio : 69.30 (As of Jun. 11, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Eli Lilly and Co Cyclically Adjusted PB Ratio?

As of today (2024-06-11), Eli Lilly and Co's current share price is C$32.57. Eli Lilly and Co's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was C$0.47. Eli Lilly and Co's Cyclically Adjusted PB Ratio for today is 69.30.

The historical rank and industry rank for Eli Lilly and Co's Cyclically Adjusted PB Ratio or its related term are showing as below:

NEOE:LLY' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 4.09   Med: 8.33   Max: 69.6
Current: 69.6

During the past years, Eli Lilly and Co's highest Cyclically Adjusted PB Ratio was 69.60. The lowest was 4.09. And the median was 8.33.

NEOE:LLY's Cyclically Adjusted PB Ratio is ranked worse than
99.33% of 745 companies
in the Drug Manufacturers industry
Industry Median: 1.89 vs NEOE:LLY: 69.60

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Eli Lilly and Co's adjusted book value per share data for the three months ended in Mar. 2024 was C$18.248. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is C$0.47 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Eli Lilly and Co Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Eli Lilly and Co's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eli Lilly and Co Cyclically Adjusted PB Ratio Chart

Eli Lilly and Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.17 13.64 22.03 28.80 46.99

Eli Lilly and Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.87 36.73 42.35 46.99 62.60

Competitive Comparison of Eli Lilly and Co's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Cyclically Adjusted PB Ratio falls into.



Eli Lilly and Co Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Eli Lilly and Co's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=32.57/0.47
=69.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Eli Lilly and Co's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=18.248/131.7762*131.7762
=18.248

Current CPI (Mar. 2024) = 131.7762.

Eli Lilly and Co Quarterly Data

Book Value per Share CPI Adj_Book
201406 17.431 100.560 22.842
201409 17.474 100.428 22.928
201412 15.962 99.070 21.232
201503 16.964 99.621 22.440
201506 16.364 100.684 21.417
201509 18.223 100.392 23.920
201512 18.079 99.792 23.873
201603 17.985 100.470 23.589
201606 17.098 101.688 22.157
201609 18.510 101.861 23.946
201612 16.973 101.863 21.957
201703 17.023 102.862 21.808
201706 17.027 103.349 21.710
201709 16.605 104.136 21.012
201712 13.456 104.011 17.048
201803 17.194 105.290 21.519
201806 14.121 106.317 17.503
201809 15.968 106.507 19.757
201812 12.493 105.998 15.531
201903 3.416 107.251 4.197
201906 3.825 108.070 4.664
201909 4.665 108.329 5.675
201912 3.585 108.420 4.357
202003 4.491 108.902 5.434
202006 5.799 108.767 7.026
202009 6.676 109.815 8.011
202012 7.554 109.897 9.058
202103 9.037 111.754 10.656
202106 8.233 114.631 9.464
202109 10.275 115.734 11.699
202112 12.052 117.630 13.501
202203 12.427 121.301 13.500
202206 11.514 125.017 12.137
202209 14.137 125.227 14.876
202212 15.226 125.222 16.023
202303 16.130 127.348 16.691
202306 15.485 128.729 15.852
202309 15.993 129.860 16.229
202312 15.222 129.419 15.499
202403 18.248 131.776 18.248

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Eli Lilly and Co  (NEOE:LLY) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Eli Lilly and Co Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Eli Lilly and Co's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Eli Lilly and Co (NEOE:LLY) Business Description

Address
Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Eli Lilly and Co (NEOE:LLY) Headlines